Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape

por Oosting, Sjoukje F, Fehrmann, Rudolf S, de Vries, Elisabeth G E
Publicado en ESMO Open (2017)

Regulators of homologous recombination repair as novel targets for cancer treatment

por Krajewska, Małgorzata, Fehrmann, Rudolf S. N., de Vries, Elisabeth G. E., van Vugt, Marcel A. T. M.
Publicado en Front Genet (2015)

Immune microenvironment composition in non‐small cell lung cancer and its association with survival

por Tamminga, Menno, Hiltermann, Thijo Jeroen N, Schuuring, Ed, Timens, Wim, Fehrmann, Rudolf SN, Groen, Harry JM
Publicado en Clin Transl Immunology (2020)

Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage

por Altena, Renske, Fehrmann, Rudolf S. N., Boer, Hink, de Vries, Elisabeth G. E., Meijer, Coby, Gietema, Jourik A.
Publicado en PLoS One (2015)

Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types

por Lamberts, Laetitia E., de Groot, Derk Jan A., Bense, Rico D., de Vries, Elisabeth G.E., Fehrmann, Rudolf S.N.
Publicado en Oncotarget (2015)

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer

por Workel, Hagma H., van Rooij, Nienke, Plat, Annechien, Spierings, Diana C.J., Fehrmann, Rudolf S. N., Nijman, Hans W., de Bruyn, Marco
Publicado en Int J Mol Sci (2020)

Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy

por Steggink, Lars C., Boer, Hink, Meijer, Coby, Lefrandt, Joop D., Terstappen, Leon W. M. M., Fehrmann, Rudolf S. N., Gietema, Jourik A.
Publicado en Pharmacogenomics J (2020)

BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity

por Heijink, Anne Margriet, Talens, Francien, Jae, Lucas T., van Gijn, Stephanie E., Fehrmann, Rudolf S. N., Brummelkamp, Thijn R., van Vugt, Marcel A. T. M.
Publicado en Nat Commun (2019)

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

por Stutvoet, Thijs S, Kol, Arjan, de Vries, Elisabeth GE, de Bruyn, Marco, Fehrmann, Rudolf SN, Terwisscha van Scheltinga, Anton GT, de Jong, Steven
Publicado en J Pathol (2019)

Transcriptional effects of copy number alterations in a large set of human cancers

por Bhattacharya, Arkajyoti, Bense, Rico D., Urzúa-Traslaviña, Carlos G., de Vries, Elisabeth G. E., van Vugt, Marcel A. T. M., Fehrmann, Rudolf S. N.
Publicado en Nat Commun (2020)

An mRNA expression-based signature for oncogene-induced replication-stress

por Llobet, Sergi Guerrero, Bhattacharya, Arkajyoti, Everts, Marieke, Kok, Klaas, van der Vegt, Bert, Fehrmann, Rudolf S.N., van Vugt, Marcel A.T.M.
Publicado en Oncogene (2022)

Improving gene function predictions using independent transcriptional components

por Urzúa-Traslaviña, Carlos G., Leeuwenburgh, Vincent C., Bhattacharya, Arkajyoti, Loipfinger, Stefan, van Vugt, Marcel A. T. M., de Vries, Elisabeth G. E., Fehrmann, Rudolf S. N.
Publicado en Nat Commun (2021)

Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors

por Kok, Yannick P., Guerrero Llobet, Sergi, Schoonen, Pepijn M., Everts, Marieke, Bhattacharya, Arkajyoti, Fehrmann, Rudolf S. N., van den Tempel, Nathalie, van Vugt, Marcel A. T. M.
Publicado en Oncogenesis (2020)

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

por Peters, Marloes A. M., Meijer, Coby, Fehrmann, Rudolf S. N., Walenkamp, Annemiek M. E., Kema, Ido P., de Vries, Elisabeth G. E., Hollema, Harry, Oosting, Sjoukje F.
Publicado en Pathol Oncol Res (2019)

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

por He, Yuan, Bouwstra, Renee, Wiersma, Valerie R., de Jong, Mathilde, Jan Lourens, Harm, Fehrmann, Rudolf, de Bruyn, Marco, Ammatuna, Emanuele, Huls, Gerwin, van Meerten, Tom, Bremer, Edwin
Publicado en Nat Commun (2019)

Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma

por Brahm, Cyrillo G, Abdul, U Kulsoom, Houweling, Megan, van Linde, Myra E, Lagerweij, Tonny, Verheul, Henk M W, Westerman, Bart A, Walenkamp, Annemiek M E, Fehrmann, Rudolf S N
Publicado en Neurooncol Adv (2020)

Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets

por Hartmans, Elmire, Orian-Rousseau, Veronique, Matzke-Ogi, Alexandra, Karrenbeld, Arend, de Groot, Derk Jan A., de Jong, Steven, van Dam, Gooitzen M., Fehrmann, Rudolf S.N., Nagengast, Wouter B.
Publicado en Theranostics (2017)

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

por Bense, Rico D., Sotiriou, Christos, Piccart-Gebhart, Martine J., Haanen, John B. A. G., van Vugt, Marcel A. T. M., de Vries, Elisabeth G. E., Schröder, Carolien P., Fehrmann, Rudolf S. N.
Publicado en J Natl Cancer Inst (2016)

TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells

por van Gijn, Stephanie E., Wierenga, Elles, van den Tempel, Nathalie, Kok, Yannick P., Heijink, Anne Margriet, Spierings, Diana C. J., Foijer, Floris, van Vugt, Marcel A. T. M., Fehrmann, Rudolf S. N.
Publicado en Oncogene (2018)

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach

por de Jong, Mathilde R. W., Visser, Lydia, Huls, Gerwin, Diepstra, Arjan, van Vugt, Marcel, Ammatuna, Emanuele, van Rijn, Rozemarijn S., Vellenga, Edo, van den Berg, Anke, Fehrmann, Rudolf S. N., van Meerten, Tom
Publicado en PLoS One (2018)